Top

Urolithiasis

Published in:

01-10-2019 | Letter to the Editor

Recurrent kidney stones in a family with a mitochondrial disorder due to the m.3243A>G mutation

Authors: M. Bargagli, G. Primiano, A. Primiano, J. Gervasoni, A. Naticchia, S. Servidei, G. Gambaro, P. M. Ferraro

Published in: Urolithiasis | Issue 5/2019

Excerpt

Dear Editor, …

Lightowlers RN, Taylor RW, Turnbull DM (2015) Mutations causing mitochondrial disease: what is new and what challenges remain? Science 349:1494–1499. https://doi.org/10.1126/science.aac7516 CrossRefPubMed

DiMauro S, Schon EA, Carelli V, Hirano M (2013) The clinical maze of mitochondrial neurology. Nat Rev Neurol 9:429–444. https://doi.org/10.1038/nrneurol.2013.126 CrossRefPubMedPubMedCentral

Emma F, Montini G, Parikh SM, Salviati L (2016) Mitochondrial dysfunction in inherited renal disease and acute kidney injury. Nat Rev Nephrol 12:267–280. https://doi.org/10.1038/nrneph.2015.214 CrossRefPubMedPubMedCentral

Emma F, Bertini E, Salviati L, Montini G (2012) Renal involvement in mitochondrial cytopathies. Pediatr Nephrol Berl Ger 27:539–550. https://doi.org/10.1007/s00467-011-1926-6 CrossRef

Pickett SJ, Grady JP, Ng YS et al (2018) Phenotypic heterogeneity in m.3243A>G mitochondrial disease: the role of nuclear factors. Ann Clin Transl Neurol 5:333–345. https://doi.org/10.1002/acn3.532 CrossRefPubMedPubMedCentral

Mancuso M, Orsucci D, Angelini C et al (2014) The m.3243A >G mitochondrial DNA mutation and related phenotypes. A matter of gender? J Neurol 261:504–510. https://doi.org/10.1007/s00415-013-7225-3 CrossRefPubMed

Hotta O, Inoue CN, Miyabayashi S et al (2001) Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int 59:1236–1243. https://doi.org/10.1046/j.1523-1755.2001.0590041236.x CrossRefPubMed

Sproule DM, Kaufmann P (2008) Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann NY Acad Sci 1142:133–158. https://doi.org/10.1196/annals.1444.011 CrossRefPubMed

Gafni RI, Brahim JS, Andreopoulou P et al (2012) Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res 27:1811–1820. https://doi.org/10.1002/jbmr.1627 CrossRefPubMedPubMedCentral

10.

Miller PD, Bilezikian JP, Diaz-Curiel M et al (2009) Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2006-2439 CrossRefPubMedPubMedCentral

11.

Chow J, Rahman J, Achermann JC et al (2017) Mitochondrial disease and endocrine dysfunction. Nat Rev Endocrinol 13:92–104. https://doi.org/10.1038/nrendo.2016.151 CrossRefPubMed

12.

Tanaka K, Takada Y, Matsunaka T et al (2000) Diabetes mellitus, deafness, muscle weakness and hypocalcemia in a patient with an A3243G mutation of the mitochondrial DNA. Intern Med Tokyo Jpn 39:249–252CrossRef

13.

O’Toole JF (2014) Renal manifestations of genetic mitochondrial disease. Int J Nephrol Renov Dis 7:57–67. https://doi.org/10.2147/IJNRD.S37887 CrossRef

14.

Nota B, Struys EA, Pop A et al (2013) Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined d-2- and l-2-hydroxyglutaric aciduria. Am J Hum Genet 92:627–631. https://doi.org/10.1016/j.ajhg.2013.03.009 CrossRefPubMedPubMedCentral

15.

Gafni RI, Langman CB, Guthrie LC et al Hypocitraturia is an untoward side effect of synthetic human parathyroid hormone (hPTH) 1-34 therapy in hypoparathyroidism that may increase renal morbidity. J Bone Miner Res 0: https://doi.org/10.1002/jbmr.3480 CrossRef

16.

Gambaro G, Vezzoli G, Casari G et al (2004) Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 44:963–986CrossRef

Title: Recurrent kidney stones in a family with a mitochondrial disorder due to the m.3243A>G mutation
Authors: M. Bargagli
G. Primiano
A. Primiano
J. Gervasoni
A. Naticchia
S. Servidei
G. Gambaro
P. M. Ferraro
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Published in: Urolithiasis / Issue 5/2019
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-018-1087-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Recurrent kidney stones in a family with a mitochondrial disorder due to the m.3243A>G mutation

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2019

Baseline chronic kidney disease does not predict long-term renal functional decline after percutaneous nephrolithotomy

Vision for the future on urolithiasis: research, management, education and training—some personal views

Adolescents with urinary stones have elevated urine levels of inflammatory mediators

New techniques on uropaleopathology

Factors affecting infectious complications following flexible ureterorenoscopy

Protective effect of pentoxifylline on oxidative renal cell injury associated with renal crystal formation in a hyperoxaluric rat model